

# Consensus-Based Recommendations for Standardizing Terminology and Reporting Adverse Events for Emergency Department Procedural Sedation and Analgesia in Children

Maala Bhatt, MD  
 Robert M. Kennedy, MD  
 Martin H. Osmond, MDCM  
 Baruch Krauss, MD, EdM  
 John D. McAllister, MD  
 J. Mark Ansermino, MBBCh, MSc  
 Lisa M. Evered, MD, MSc  
 Mark G. Roback, MD  
 Consensus Panel on Sedation  
 Research of Pediatric  
 Emergency Research Canada  
 (PERC) and the Pediatric  
 Emergency Care Applied  
 Research Network (PECARN)

From the Division of Emergency Medicine, Montreal Children's Hospital, McGill University, Montreal, Quebec, Canada (Bhatt); the Division of Emergency Medicine (Kennedy) and Division of Pediatric Anesthesiology (McAllister), St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO; the Division of Emergency Medicine, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada (Osmond); the Division of Emergency Medicine, Children's Hospital Boston, Harvard Medical School, Boston, MA (Krauss); the Department of Pediatric Anesthesia, British Columbia Children's Hospital, University of British Columbia, Vancouver, British Columbia, Canada (Ansermino); the Division of Emergency Medicine, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada (Evered); and the Division of Emergency Medicine, University of Minnesota Children's Hospital Fairview, University of Minnesota Medical School, Minneapolis, MN (Roback).

Children commonly require sedation and analgesia for procedures in the emergency department. Establishing accurate adverse event and complications rates from the available literature has been difficult because of the difficulty in aggregating results from previous studies that have used varied terminology to describe the same adverse events and outcomes. Further, serious adverse events occur infrequently, necessitating the study of large numbers of children to assess safety. These limitations prevent the establishment of a sufficiently large database on which evidence-based practice guidelines may be based. We assembled a panel of pediatric sedation researchers and experts to develop consensus-based recommendations for standardizing procedural sedation and analgesia terminology and reporting of adverse events. Our goal was to create a uniform reporting mechanism for future studies to facilitate the aggregation and comparison of results. [Ann Emerg Med. 2009;53:426-435.]

0196-0644/\$-see front matter  
 Copyright © 2008 by the American College of Emergency Physicians.  
 doi:10.1016/j.annemergmed.2008.09.030

## SEE EDITORIAL, P. 436.

### INTRODUCTION AND IMPORTANCE

A large number of children receive procedural sedation and analgesia for diagnostic and therapeutic procedures in emergency departments (EDs) each year. Although it is critical to establish evidence-based practice in procedural sedation, efforts have been limited by an inability to aggregate results from existing studies. Practice is varied and results are reported inconsistently because investigators do not have a standardized set of definitions and reporting guidelines to follow.<sup>1-11</sup>

Using the same definitions to describe sedation practices, interventions, adverse events and time intervals is an important first step to facilitate comparisons between studies and the aggregation of data from multiple studies.<sup>12-15</sup> Well-defined adverse events reported in studies of sufficiently large patient populations will permit improved assessment of procedural sedation risk and patient outcomes.

### Goals and Objectives

Following the International Liaison Committee on Resuscitation Task Force on Cardiac Arrest and Cardiopulmonary Resuscitation Outcomes that developed uniform definitions and reporting templates in the "Utstein

style” to standardize research reporting of cardiac arrest,<sup>16</sup> we created standardized definitions for sedation-related terms, adverse events, and time intervals. We also propose consensus-based recommendations for uniform adverse event reporting based on review of the existing pediatric sedation literature.

It is our intention that the definitions and reporting framework presented here be adopted by sedation researchers and used in future procedural sedation investigations.

## MATERIALS AND METHODS

In July 2007, we assembled a panel of experts in procedural sedation and analgesia from 2 national collaborative pediatric emergency medicine research networks to establish consensus on uniform terms, definitions, and reporting for pediatric ED procedural sedation and analgesia. The panel chairs (M.B. and M.G.R.) approached the leadership of Pediatric Emergency Research Canada (PERC) and the Pediatric Emergency Care Applied Research Network (PECARN) for recommendations within their membership for researchers who had a particular expertise in emergency medicine, procedural sedation and analgesia, or patient safety. The panel chairs selected a representative group, composed of 6 pediatric emergency physicians and 2 pediatric anesthesiologists. PERC and PECARN were equally represented. These 2 national collaborative research networks represent institutions that care for approximately 1.3 million children annually in 34 EDs.

A reference list was generated from a MEDLINE search (1950 to week 1 July 2007), using the search strategy (sedation OR anesthesia OR analgesia) AND (emergency department OR pediatrics) AND (adverse event OR adverse outcome). We identified all articles from emergency medicine or anesthesia that contained information on sedation-related adverse outcomes, searched the bibliographies of all identified articles, and queried the expert panel for additional relevant articles. A draft list of sedation terms, adverse events, and definitions of these items found in the reference list articles was compiled and circulated to panel members. Consensus was reached on which events should be routinely reported in future pediatric ED sedation studies.

We used electronic communication, teleconferencing, and one face-to-face meeting to review the literature, discuss terminology, and reach consensus on definitions and recommendations for uniform reporting of adverse events. All members participated in discussions on each topic, and consensus was reached through debate and dialogue that was not time limited. Some terms and concepts, including laryngospasm, depth of sedation, and determining the optimal format for the definitions of adverse events, were more difficult to ratify. Disagreement between panel members was resolved through repeated discussion (teleconference and face-to-face meeting) until unanimous group consensus was reached. During a meeting at Mont Tremblant, Quebec, on January 28, 2008, the panel rediscussed all terms and ratified their definitions. When the existing literature was deemed insufficient to come to a consensus agreement on definition, recommendations for data

collection pertinent to a given term were made and direction for future study required to develop definitive definitions was provided.

Determining the optimal measure to define adverse events was the greatest challenge of this project, resulting in one of the most difficult decision points for the panel. The pros and cons of including a discrete threshold and duration of an event (eg, an oximeter reading of less than 90% for 30 seconds or longer for oxygen desaturation) or interventions performed in response to the event in the definitions were discussed at length. Although using the traditional structure of a prespecified threshold and duration to describe adverse events is the most obvious and, ostensibly, objective approach, the panel believed that this method may yield inaccurate and unreliable results. Using a single numeric value to identify patients who have experienced an adverse event has several important limitations: a single threshold may *miss* clinically significant events (eg, a child with a precipitous oxygen desaturation requiring airway maneuvers, who does not meet the absolute number threshold required to be considered an adverse event), is prone to mechanical artifact, leading to detection of clinically insignificant events (eg, oximeter reads 88% but resolves spontaneously before the clinician intervenes), and is not uniformly applicable (eg, may not be meaningful at higher altitudes). Further, and perhaps most significantly, the duration of an event is particularly difficult to assess in a clinical setting where precise measurement of time intervals is inaccurate and somewhat arbitrary when left to the clinician’s best estimation.

Intervention-based definitions were chosen because the panel believes this framework will yield the greatest possibility of uniform data collection for clinically important events. Definitions using this approach require specific clinical criteria to be present *and* for one or more interventions to be performed with the intention of treating or managing the event. The presence or absence of an intervention performed in response to a clinical event is a reproducible measure and reflects the clinician’s interpretation of the significance of the event in the clinical context. The panel does recognize that interventions *performed* reflect the provider’s clinical judgment and experience and may not necessarily be absolutely *required*. However, by including the number and type of interventions performed, as well as the documentation of objective characteristics (eg, lowest reliable oxygen saturation observed), researchers will be able to determine the severity and significance of each event.

The panel considered several hypothetical scenarios of adverse events, and all would have had 1 or more intervention(s) performed. An intervention could have been as simple as airway repositioning. We contend that researchers are not concerned with events that are extremely short lived (seconds) or resolve spontaneously (error in equipment reading or are an expected physiologic effect) and thus are of questionable clinical significance. Documenting interventions performed yields reproducible measures that will lead to more standardized and accurate data collection. Although this approach is not

instinctive, it is our belief that it will allow sedation researchers to collect a robust data set of clinically important adverse events with a range of severity defined by the number and type of interventions performed while minimizing the recording of events whose significance is difficult to interpret.

Our intent was to create a comprehensive core data set of adverse events to be reported. Researchers may choose to study a subset of terms applicable to their chosen study hypothesis. Similarly, for their specific research needs they may add to this data set as they desire.

The content of this article has been endorsed by the research networks of PERC and PECARN.

## SEDATION TERMINOLOGY

### Procedural Sedation and Analgesia

**Definition.** Procedural sedation and analgesia, commonly referred to as “sedation,” is the use of anxiolytic, sedative, analgesic, or dissociative drugs to attenuate pain, anxiety, and motion to facilitate the performance of a necessary diagnostic or therapeutic procedure, provide an appropriate degree of amnesia or decreased awareness, and ensure patient safety.<sup>17,18</sup>

**Commentary.** “Conscious sedation” is a misleading and outdated term that should no longer be used in research or clinical practice.<sup>19</sup> The use of analgesic drugs alone is not considered sedation.

### Pre sedation Assessment

**Definition.** A focused history and physical examination to determine factors that may influence the selection of the sedation technique and affect the safety of the sedation.<sup>20</sup> This evaluation includes ascertainment of current or past patient health issues, the indications for sedation, previous patient experience with sedation or anesthesia, and the presence of airway or other conditions that may affect the efficacy of the sedation or the incidence of side effects, adverse events, or complications.

**Rationale.** Patients exhibit variable responses to sedative and analgesic drugs. The pre sedation assessment guides the selection of the sedation technique. Drug dose requirements, depth of sedation, and frequency of adverse events may be influenced by a variety of patient factors such as age, coexisting illness or injury, pharmacogenetic factors, and psychological or anatomic variability. Documentation of relevant factors gleaned during the pre sedation assessment and correlation with adverse events may lead to improved recognition of specific risk factors for sedation-related adverse events. Future procedural sedation and analgesia research will progress by identifying risk factors for adverse events and by evaluating strategies to minimize sedation-related adverse events. We recommend that future research include a statement that this assessment was performed and that relevant patient or situational risk factors and potentially confounding variables were assessed in the context of the specific research question.

### Pre sedation State

**Definition.** The patient’s behavioral state immediately before sedation. A child’s behavior can be characterized as calm (eg, not crying), agitated but responds to comforting (eg, briefly stops crying), or agitated and does not respond to comforting (eg, continuous crying).

**Rationale.** A child’s behavioral state before sedation may affect the dose of sedative required, unpleasant recall of the procedure, or unpleasant recovery reactions.<sup>5,21,22</sup> Pre sedation agitation has been described by several authors, but no definitions or validated measures exist. Two studies have collected data on this entity: one using a visual analog scale<sup>22</sup> to rate the degree of agitation and the other using an ordinal scale.<sup>23</sup> Because of limitations in using a single visual analog scale measurement to compare groups of individuals,<sup>24</sup> and in the absence of a validated measure, we suggest using a simple ordinal scale to describe the patient’s behavior. We recommend that investigators describe in the methods section how a child’s behavioral state was assessed and any interventions that were performed to affect this state.

### Depth of Sedation

**Definition.** Depth of sedation has been qualitatively defined and described as a continuum, progressing from mild through moderate to deep sedation and potentially to general anesthesia.<sup>25-29</sup> Identifying depth of sedation is important because it is believed that the risk of adverse events increases as patients become more deeply sedated. The correlation between depth of sedation and risk of adverse events is altered with ketamine because of its unique dissociative properties.<sup>20,30-32</sup>

**Rationale.** Depth of sedation should be part of the patient assessment and reported in research to help understand the efficacy and safety of the sedation technique. Scales commonly used to assess depth of sedation were developed to determine a patient’s state of recovery or have not been validated in the ED setting.<sup>33-36</sup> Because of these limitations, we are unable to endorse a specific tool or definition for this term. Further research is needed to objectively define the stages on the continuum and to create or validate a tool for use in the ED setting. It is important for investigators to state in the methods section how depth of sedation is quantified.

### Efficacy of Sedation

**Definition.** The creation of conditions necessary to safely facilitate the completion of a procedure through attenuation of pain, anxiety and movement with amnesia or decreased awareness.<sup>11,17,18</sup> All of the following criteria must be present for a sedation to be considered efficacious.<sup>37</sup>

- a) The patient does not have unpleasant recall of the procedure.
- b) The patient did not experience sedation-related adverse events resulting in
  - abandonment of the procedure *or*
  - a permanent complication (Section VIII) *or*
  - an unplanned admission to the hospital or prolonged ED observation

- c) The patient did not actively resist or require physical restraint for completion of the procedure. The need for minimal redirection of movements should not be considered as active resistance or physical restraint.

**Commentary.** Presence of any of the above criteria is considered a sedation failure.

**Rationale.** Previous researchers have described sedation failure as the inability to complete a procedure because of patient anxiety, pain, or distress.<sup>9</sup> We have expanded this definition to include the patient's perception of efficacy (lack of unpleasant recall of the procedure) and have added a measure of safety in delivering the sedation. We are unable to endorse a specific measure of patient distress because there are no validated tools that are easily applicable in this setting. Further research is needed to objectively define and quantify this term in the ED setting. It is important for investigators to state in the methods section how efficacy of sedation is quantified.

### Readiness for Discharge

**Definition.** The time at which a patient emerges from the effects of sedation to a level of consciousness that reflects satisfactory physiologic recovery (ability to achieve a satisfactory state of wakefulness and maintain a patent airway without respiratory depression and return to baseline motor function and vital signs) *and* demonstrates adequate pain control.

**Rationale.** Readiness for discharge is an important outcome measure in sedation research because it defines clinical recovery from the pharmacologic effects of sedation. Reporting time to physiologic recovery will allow researchers to identify trends and quantify recovery times for sedation agents. We recommend that investigators document the time to physiologic recovery in addition to the time of actual ED discharge because many factors unrelated to a patient's recovery from sedation such as the availability of diagnostic imaging, consultants, ED staff, and ED patient census influence the time a patient is actually discharged from the ED. Many consensus-based criteria exist to confirm a patient's readiness for discharge; however, none have been objectively studied or validated. Further research is needed to objectively define and quantify this term in the ED setting. We recommend that investigators document in the methods section criteria used to define readiness for discharge.

### SEDATION INTERVALS

The time of sedation may be broken into 4 distinct intervals or phases: presedation, sedation, ED recovery, and postdischarge. Definitions, as well as subphases, are listed and defined in the Figure. It has been postulated that patients' risk for certain adverse events varies with their phase of sedation. Further study of adverse events and severity by sedation interval is warranted. We recommend that investigators record the times a patient begins and ends all phases and subphases.

### ADVERSE EVENT TERMINOLOGY

Accurate reporting of adverse events, the circumstances surrounding these events, and the interventions that result from

their occurrence are of vital importance in the identification of the risk factors for and causes of adverse events associated with procedural sedation. The panel has recommended reporting all sedation events that result in an intervention or a change in disposition from the ED. All clinically relevant events, from minor (eg, mild desaturation requiring a jaw thrust) to more serious (eg, clinically apparent pulmonary aspiration), will be captured with this method. Only transient or minor physiologic effects that have no clinical consequence (eg, minor changes in the pulse rate, respiratory rate, and blood pressure caused by many sedation drugs) will not be detected with this framework. These events do not require a change in the sedation plan and were deemed not to contribute to the understanding of the risk factors for and causes of adverse events associated with procedural sedation.

The adverse events listed below fall into several categories: respiratory (oxygenation or ventilation-associated and clinically apparent pulmonary aspiration), vomiting, cardiovascular (bradycardia and hypotension), excitatory movements (myoclonus, muscle rigidity, and generalized seizure), adverse behavioral reactions (paradoxical response to sedation and unpleasant recovery reaction), and permanent complications (neurologic injury and death).

Patients may experience more than one category of adverse events, as well as more than one type of adverse event within a given category. All events should be reported separately, even when occurring in the same category (eg, apnea associated with oxygen desaturation should be reported as 2 separate events). We provide definitions for adverse events (below), sedation intervals (Figure), and a template for adverse event data collection for sedation research (Appendix E1, available online at <http://www.annemergmed.com>).

## OXYGENATION

### 1.1 Oxygen Desaturation

**Definition.** Oxygen desaturation *and* one or more interventions are performed with the intention of improving the oxygen saturation.<sup>3,38-40</sup> The interventions include the following:

- Vigorous tactile stimulation
- Airway repositioning—chin lift, jaw thrust, neck extension, midline repositioning
- Suctioning
- Supplemental or increased oxygen delivery
- Oral or nasal airway placement
- Application of positive pressure or ventilation with bag mask
- Tracheal intubation

**Rationale.** Definitions for oxygen desaturation use a combination of threshold and duration of desaturation to describe the event (eg, oxygen saturation <90% for ≥30 seconds).<sup>41-43</sup> We chose an intervention-driven definition because a prespecified threshold may miss some cases of important desaturation. For example, a child who has been preoxygenated to 100% may experience a precipitous decrease




Figure. Sedation time intervals.

in saturation to 90% that is managed by the administration of supplemental oxygen and maneuvers to reposition the airway. This event is clinically relevant yet would be missed if a threshold alone were used to define oxygen desaturation. Further, duration of desaturation is difficult to accurately assess. All clinically significant cases will be captured in the proposed intervention-driven definition. Researchers will be able to distinguish the severity of desaturation with the documentation of lowest oxygen saturation, use of preoxygenation, and the number and type of interventions performed.

## VENTILATION

### 2.1 Apnea: Central

**Definition.** Cessation or pause of ventilatory effort *and* one or more interventions are performed with the intention of stimulating or assisting ventilation. The interventions include the following:

- Vigorous tactile stimulation
- Application of bag mask *with* assisted ventilation
- Tracheal intubation
- Administration of reversal agents (opioid or benzodiazepine antagonists)

**Rationale.** Definitions for apnea describe the event as a loss of respiratory effort for a specified duration (eg, no respiratory effort for 30 seconds).<sup>2,44-48</sup> We chose an intervention-driven definition because accurate measurement of apnea duration is difficult. Researchers will be able to verify whether patients met the definition of central apnea by documenting the criteria used for recognition of the event and will be able to assess severity by the number and type of interventions performed.

### 2.2 Apnea: Obstructive

#### 2.2.1 Partial Upper Airway Obstruction

**Definition.** Incomplete obstruction to air exchange manifested by the presence of one or more of the following:

- Stridor
- Snoring
- Chest wall and suprasternal retractions AND rapid resolution with one or more of the following interventions to treat the partial airway obstruction:<sup>9,49,50</sup>
  - Airway repositioning
  - Suctioning
  - Oral or nasal airway placement
  - Application of positive pressure with bag mask but *without* assisted ventilation

**Rationale.** Most existing studies include partial airway obstruction in a general category of respiratory adverse events.<sup>5,7,41</sup> We believe it is important to distinguish partial from complete airway obstruction because the interventions, treatments, and outcomes may be quite different. We chose a definition according to specific criteria and the requirement for either an airway maneuver or the application of positive pressure with a bag mask apparatus continuous positive airway pressure in an attempt to alleviate the obstruction.<sup>9,49</sup> Airway obstruction that does *not* rapidly and easily respond to these simple interventions does not meet the requirements for partial airway obstruction and must be reclassified.

#### 2.2.2 Complete Upper Airway Obstruction

**Definition.** Ventilatory effort with no air exchange\* *and* one or more of the following interventions are performed with the intention of relieving complete airway obstruction:

- a) Airway repositioning
- b) Suctioning
- c) Oral or nasal airway placement
- d) Application of positive pressure with bag mask +/- assisted ventilation
- e) Tracheal intubation
- f) Administration of additional sedation agents
- g) Administration of neuromuscular blockade agents

\*No air exchange is manifested by the absence of upper airway (eg, stridor or snoring) and breath sounds on auscultation and the loss of CO<sub>2</sub> waveform, when capnography is used.

### 2.3 Laryngospasm

**Definition.** Partial or complete upper airway obstruction, with oxygen desaturation caused by involuntary and sustained closure of the vocal cords *and is not* relieved by routine airway repositioning maneuvers, suctioning, or insertion of a nasal or oral airway.<sup>51,52</sup>

**Note.** A characteristic stridulous noise can be heard with partial laryngospasm but will be absent in complete laryngospasm

**Rationale.** Although laryngospasm is a subset of airway obstruction, it warrants separate data collection because of its association with commonly used sedation drugs and high likelihood for treatment with aggressive airway interventions. Laryngospasm is the sudden pathologic adduction of the vocal cords with partial or complete closure of the glottic opening and may be intermittent or sustained, brief or prolonged.<sup>51-53</sup>

Emergency physicians do not routinely visualize the airway when administering procedural sedation; therefore, laryngospasm in the ED setting is a clinical diagnosis. Laryngospasm has been reported in association with ED sedation, and these cases likely represent a spectrum of severity because several cases improved without intervention.<sup>1,5,8,10,31,40,54,55</sup> Differentiating partial airway obstruction caused by decreased muscle tone or soft tissue obstruction from incomplete laryngospasm is difficult. However, partial airway obstruction relieved by simple airway repositioning or placement of an oral or nasal airway should not be considered laryngospasm.<sup>52</sup>

Only sustained partial or complete closure of the cords associated with oxygen desaturation, not responsive to airway maneuvers, representing an acute life-threatening airway obstruction should be considered true laryngospasm.<sup>51-53</sup> The severity of the event will be further described by documenting interventions performed (eg, bag-valve-mask ventilation, administration of a muscle relaxant) in response to the laryngospasm.

### CLINICALLY APPARENT PULMONARY ASPIRATION

**Definition.** Suspicion\* *or* confirmation<sup>†</sup> of oropharyngeal or gastric contents in the trachea during the sedation or

physiologic recovery phase *and* the appearance of respiratory signs and symptoms that were not present before the sedation.<sup>56,57</sup> The new signs and symptoms must present before the end of the ED recovery phase (Figure).

#### (i) Physical signs

- Cough
- Crackles/rales
- Decreased breath sounds
- Tachypnea
- Wheeze
- Rhonchi
- Respiratory distress

#### (ii) Oxygen requirement

- Decrease in oxygen saturation from baseline, requiring supplemental oxygen

#### (iii) Chest radiograph findings

- Focal infiltrate, consolidation or atelectasis

\**Suspicion* of contents in the trachea is established if, during the sedation phase or before physiologic recovery in the ED recovery phase, (1) a patient vomits or retches (without visible gastric contents) *or* (2) there is evidence of gastric contents in the material suctioned from the oropharynx *or* (3) there is an onset of coughing with oxygen desaturation.

<sup>†</sup>*Confirmation* of contents in the trachea is established when there is direct visualization of oropharyngeal or gastric contents in the trachea on laryngoscopy.

The patient must develop one or more signs or symptoms in any of the following 3 categories:

**Rationale.** Definitions of clinically apparent pulmonary aspiration require *confirmation* of gastric secretions or particulate matter in the tracheobronchial tree by laryngoscopy or flexible bronchoscopy.<sup>58,59</sup> Emergency physicians do not routinely perform laryngoscopy in association with procedural sedation; therefore, a proviso was made for those cases in which the presence of gastric contents in the tracheobronchial tree is suspected but has not been confirmed. Suspicion of aspiration is clearly defined and is an event that leads a physician to believe that a patient may be at risk for aspiration because of the timing of the regurgitation/vomiting in relation to a patient's state of arousal. Confirmation is achieved when new respiratory signs and symptoms develop before the end of the ED recovery phase. Documentation of the factors contributing to the diagnosis of aspiration, clinical manifestations, and treatments will allow researchers to gain a better understanding of this rare entity in ED procedural sedation.

### RETCHING/VOMITING

**Definition.** The motor reflex response characteristic of retching with or without the expulsion of gastric contents through the mouth or nose that occurs during sedation, ED recovery or postdischarge phases of sedation (Figure).

If the timing and extent of vomiting present a suspicion or confirmation of clinically apparent pulmonary aspiration, this adverse event must also be documented (Section III).

**Rationale.** Retching and vomiting are unpleasant for children and their families, may increase the risk of aspiration, may increase the length of the ED stay, and are more commonly associated with certain sedative drugs. For these reasons, retching or vomiting during the sedation, ED recovery, or postdischarge phase is important and should be reported. Documenting the administration of an antiemetic as prophylaxis or treatment is also important.

## CARDIOVASCULAR EVENTS

### 5.1 Bradycardia

**Definition.** Pulse rate decreasing 2 standard deviations below normal for age as described by the American Heart Association (AHA) in the Pediatric Advanced Life Support (PALS) Provider Manual<sup>60</sup> during the sedation or physiologic recovery phase (Figure) and one or more interventions are performed with the intention of improving pulse rate and cardiac output. The interventions include the following:

- a) Suctioning
- b) Vigorous tactile stimulation
- c) Airway repositioning
- d) Supplemental oxygen
- e) Application of bag mask *with* assisted ventilation
- f) Tracheal intubation
- g) Chest compressions
- h) Administration of medications

Bradycardia may be an expected adverse effect of some drugs and is a normal finding in certain populations (eg, athletes, those with eating disorders, those taking certain medications). Bradycardia is considered an adverse event only if an intervention is performed in an attempt to improve the pulse rate and cardiac output.

**Rationale.** The AHA offers the most accepted definition for bradycardia in pediatrics and is taught during PALS. Although some studies use a percentage change in pulse rate from baseline, this is a difficult calculation to make and may lead to inaccurate reporting. An intervention-driven definition based on AHA criteria will capture all significant events of bradycardia and exclude those with a normal resting pulse rate that decreases below the AHA thresholds but is not clinically significant.

### 5.2 Hypotension

**Definition.** Systolic blood pressure less than the fifth percentile for age, as defined by the AHA in PALS<sup>61</sup> during the sedation or ED recovery phase (Figure) and one or more intervention is performed with the intention of improving the blood pressure. These interventions include administration of:

- a) IV Fluid
- b) Medications
- c) Chest compressions

Hypotension may be an expected adverse effect of some drugs used for sedation. Hypotension is considered an adverse event

only if an intervention is performed to improve the blood pressure.

**Rationale.** The AHA offers the most accepted definition for hypotension in pediatrics and is taught during PALS. Although some studies use a percentage change in blood pressure, this is a difficult calculation to make and may lead to inaccurate reporting. An intervention-driven definition based on AHA criteria will capture all clinically significant episodes of hypotension.

## EXCITATORY MOVEMENTS

### 6.1 Myoclonus

**Definition.** Involuntary, brief contraction of some muscle fibers, of a whole muscle, or of different muscles of one group, leading to movements of the corresponding body parts, usually not longer than 1/10 of a second (100 milliseconds)<sup>62</sup> and interferes with the procedure, requiring an intervention or administration of medications. Hiccupping is a form of myoclonus.

### 6.2 Muscle Rigidity

**Definition.** Involuntary muscle stiffening in extension that can be associated with shaking and interferes with the procedure, requiring an intervention or administration of medications.

### 6.3 Generalized Motor Seizure

**Definition.** Temporary abnormal neural electrophysiologic phenomenon that manifests as involuntary contractions or series of contractions of the voluntary muscles. The contractions can be sustained (tonic) or repeated (tonic-clonic).<sup>63</sup>

**Commentary.** An extreme form of muscle rigidity with shaking can resemble seizure activity; therefore, confirming a true seizure would require the use of electroencephalography.

**Rationale.** Although it is thought that the likelihood of a true seizure is low during procedural sedation and analgesia because of anticonvulsant properties of many sedation drugs, some excitatory movements can resemble tonic-clonic seizures. Rigidity with shaking cannot be distinguished from true seizure activity without concurrent electroencephalography monitoring, which is impractical during sedation in the ED. Further, it is known that some excitatory movements are more commonly associated with certain sedation drugs (eg, myoclonus with etomidate). These side effects are considered adverse events when they prolong or interrupt the procedure or require additional medications to treat the movements.

## ADVERSE BEHAVIORAL REACTIONS

### 7.1 Paradoxical Response to Sedation

**Definition.** Unanticipated restlessness or agitation in response to the administration of sedation drugs occurring during the sedation phase and results in the unplanned administration of reversal agents or alternative sedation drug(s),

or results in a delay in the completion or discontinuation of the procedure.<sup>64</sup>

**Rationale.** Paradoxical reactions to sedation drugs have been reported and often result in an alteration or discontinuation of the sedation plan. These events are important and should be reported in research.

## 7.2 Unpleasant Recovery Reactions

**Definition.** Abnormal patient affect or behaviors during the ED recovery phase<sup>11,22,54,55,65</sup> (Figure) that requires additional treatment and a change or delay in patient discharge from the ED. The behaviors include one or more of the following<sup>54,66</sup>:

- Crying—Inconsolable
- Agitation—Restless, continuous activity
- Delirium—State of severe confusion
- Dysphoria—Inappropriate mood of sadness
- Nightmares—Unpleasant dreams
- Hallucinations—Responds to sensory phenomena (ie, seeing, hearing, or feeling) that are not physically present.

**Rationale.** Many terms have been used to describe this event. We have chosen to restrict this definition to unpleasant reactions that result in an unexpected intervention. Documentation of a patient's recall of the event will be important to determine the clinical significance of these events.

## PERMANENT COMPLICATIONS

### 8.1 Permanent Neurologic Injury

**Definition.** A neurologic deficit that was not present before sedation and does not resolve.

**Commentary.** This definition requires follow-up to confirm that the deficit was not transient.

### 8.2 Death

The irreversible cessation of cerebral function, spontaneous function of the respiratory system, and spontaneous function of the circulatory system.<sup>67</sup>

## OTHER

Any effect of sedation not specifically mentioned above that results in an unexpected intervention should be described and documented.

## DISCUSSION

In this article, our consensus panel proposes a framework of definitions and recommendations for reporting sedation terminology, time intervals, and adverse events for procedural sedation research. It is our goal that through this standardization, future sedation studies will generate data that may be readily compared and aggregated. It is our further intention that this work facilitate study of the large populations of patients required to allow for definitive clinical care guidelines to be devised that will ensure the safety of ED procedural sedation and analgesia in children.

Although we believe that uniform reporting of adverse events will improve pediatric procedural sedation research, this approach must be interpreted in light of several important limitations. First, the proposed definitions represent a consensus opinion. Every effort was made to develop evidence-based definitions; however, this was often not possible because of the paucity of existing information. Second, our intervention-based approach to definitions is not commonly used in current sedation research. Although we believe this method will yield a more objective, uniform data set, the deviation from the traditionally used "threshold and duration" approach may initially be met with resistance from sedation researchers. It is our desire that Appendix E1 (available online at <http://www.annemergmed.com>) will provide researchers with a reporting template that will ease the transition to intervention-based definitions in sedation research. Third, the definitions and data collection template have not been piloted. According to the Utstein experience, with incorporation into general use, we expect that some adaptations to the reporting framework will be needed in the future. The panel is committed to following this forward and making modifications as needed. Finally, as reflected by the experience of the panel, the focus of our recommendations was on children undergoing procedural sedation and analgesia in the ED; however, the same principles could be applied to patients of all ages and to other sedation settings outside of the operating room.

---

*Supervising editor:* Steven M. Green, MD

*Funding and support:* By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article, that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. This work was supported by a Canadian Institutes of Health Research Team Grant in Pediatric Emergency Medicine.

*Publication dates:* Received for publication June 10, 2008. Revision received September 11, 2008. Accepted for publication September 26, 2008. Available online November 20, 2008.

*Address for correspondence:* Maala Bhatt, MD, Division of Emergency Medicine, Montreal Children's Hospital, 2300 Tupper Street, Rm T-122, Montreal, QC, H3H 1P3 Canada; 514-412-4400 ext 22740, fax 514-412-4397; E-mail [maala.bhatt@muhc.mcgill.ca](mailto:maala.bhatt@muhc.mcgill.ca).

## REFERENCES

- Lightdale JR, Goldmann DA, Feldman HA, et al. Microstream capnography improves patient monitoring during moderate sedation: a randomized controlled trial. *Pediatrics*. 2006;117:e1170-1178.
- Barbi E, Gerarduzzi T, Marchetti F, et al. Deep sedation with propofol by nonanesthesiologists: a prospective pediatric experience. *Arch Pediatr Adolesc Med*. 2003;157:1097-1103.

3. Pena BM, Krauss B. Adverse events of procedural sedation and analgesia in a pediatric emergency department. *Ann Emerg Med.* 1999;34(4 pt 1):483-491.
4. Roback MG, Bajaj L, Wathen JE, et al. Preprocedural fasting and adverse events in procedural sedation and analgesia in a pediatric emergency department: are they related? *Ann Emerg Med.* 2004;44:454-459.
5. Roback MG, Wathen JE, Bajaj L, et al. Adverse events associated with procedural sedation and analgesia in a pediatric emergency department: a comparison of common parenteral drugs. *Acad Emerg Med.* 2005;12:508-513.
6. Sacchetti A, Stander E, Ferguson N, et al. Pediatric procedural sedation in the community emergency department: results from the ProSCED registry. *Pediatr Emerg Care.* 2007;23:218-222.
7. Agrawal D, Manzi SF, Gupta R, et al. Preprocedural fasting state and adverse events in children undergoing procedural sedation and analgesia in a pediatric emergency department. *Ann Emerg Med.* 2003;42:636-646.
8. Bell A, Treston G, McNabb C, et al. Profiling adverse respiratory events and vomiting when using propofol for emergency department procedural sedation. *Emerg Med Australas.* 2007;19:405-410.
9. Guenther E, Pribble CG, Junkins EP Jr, et al. Propofol sedation by emergency physicians for elective pediatric outpatient procedures. *Ann Emerg Med.* 2003;42:783-791.
10. Wood C, Hurley C, Wettlaufer J, et al. Retrospective comparison of emergency department length of stay for procedural sedation and analgesia by nurse practitioners and physicians. *Pediatr Emerg Care.* 2007;23:709-712.
11. Pitetti RD, Singh S, Pierce MC. Safe and efficacious use of procedural sedation and analgesia by nonanesthesiologists in a pediatric emergency department. *Arch Pediatr Adolesc Med.* 2003;157:1090-1096.
12. Cummings RO, Chamberlain DA, Abramson NS, et al. Recommended guidelines for uniform reporting of data from out-of-hospital cardiac arrest: the Utstein Style. A statement for health professionals from a task force of the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada and the Australian Resuscitation Council. *Circulation.* 1991;84:960-975.
13. Idris AH, Berg RA, Bierens BJ, et al. Recommended guidelines for uniform reporting of data from drowning: the "Utstein Style." *Circulation.* 2003;108:2565-2574.
14. Dick WF, Baskett PJ, Grande C, et al. Recommendations for uniform reporting of data following major trauma—the Utstein style. An international Trauma Anaesthesia and Critical Care Society (ITACCS) initiative. *Br J Anaesth.* 2000;84:818-819.
15. Hollander JE, Blomkalns AL, Brogan GX, et al. Standardized reporting guidelines for studies evaluating risk stratification of ED patients with potential acute coronary syndromes. *Acad Emerg Med.* 2004;11:1331-1340.
16. Jacobs I, Nadkarni V, Bahr J, et al. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries: a statement for healthcare professionals from a task force of the international liaison committee on resuscitation. *Circulation.* 2004;110:3385-3397.
17. Krauss B, Green SM. Procedural sedation and analgesia in children. *Lancet.* 2006;367:766-780.
18. Krauss B, Green SM. Sedation and analgesia for procedures in children. *N Engl J Med.* 2000;342:938-945.
19. Green SM, Krauss B. Procedural sedation terminology: moving beyond "conscious sedation." *Ann Emerg Med.* 2002;39:433-435.
20. Green SM, Roback MG, Miner J, et al. Fasting and emergency department procedural sedation and analgesia: a consensus-based clinical practice advisory. *Ann Emerg Med.* 2007;49:454-461.
21. Kennedy RM, McAllister JD. Midazolam with ketamine: who benefits? *Ann Emerg Med.* 2000;35:297-299.
22. Sherwin TS, Green SM, Khan A, et al. Does adjunctive midazolam reduce recovery agitation after ketamine sedation for pediatric procedures? a randomized, double-blind, placebo-controlled trial. *Ann Emerg Med.* 2000;35:229-238.
23. McGlone R, Fleet T, Durham S, et al. A comparison of intramuscular ketamine with high dose intramuscular midazolam with and without intranasal flumazenil in children before suturing. *Emerg Med J.* 2001;18:34-38.
24. Streiner DL, Norman GR. *Continuous Judgements. Health Measurement Scales.* 3rd ed. Oxford, UK: Oxford University Press; 2003:33-34.
25. Burton JH, Miner J. *Emergency Sedation and Pain Management.* New York, NY: Cambridge University Press; 2008.
26. Cote CJ, Wilson S. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: an update. *Pediatrics.* 2006;118:2587-2602.
27. Gross JB, Farmington CT, Bailey PL, et al. American Society of Anesthesiology Task Force on Sedation and Analgesia by Non-Anesthesiologists. Practice Guidelines for sedation and analgesia by non-anesthesiologists. *Anesthesiology.* 2002;96:1004-1017.
28. Committee on Drugs. Section on Anesthesiology. Guidelines for the elective use of conscious sedation, deep sedation, and general anesthesia in pediatric patients. *Pediatrics.* 1985;76:317-321.
29. Goodwin SA, Caro DA, Wolf SJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. *Ann Emerg Med.* 2005;45:177-196.
30. Green SM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation in children. *Ann Emerg Med.* 2004;44:460-471.
31. Green SM, Rothrock SG, Lynch EL, et al. Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. *Ann Emerg Med.* 1998;31:688-697.
32. Green SM, Krauss B. Pulmonary aspiration risk during emergency department procedural sedation—an examination of the role of fasting and sedation depth. *Acad Emerg Med.* 2002;9:35-42.
33. Hoffman R, Nowakowski R, Troshynski TJ, et al. Risk reduction in pediatric procedural sedation by application of an American Academy of Pediatrics/American Society of Anesthesiologists process model. *Pediatrics.* 2002;109:236-243.
34. Ramsay M, Savege T, Simpson B, et al. Controlled sedation with alphaxalone-alphadolone. *BMJ.* 1974;2:656-659.
35. Aldrete JA, Kroulik D. A postanesthetic recovery score. *Anesth Analg.* 1970;49:929-934.
36. Ambuel B, Hamlett KW, Marx CM, et al. Assessing distress in pediatric intensive care environments: the COMFORT Scale. *J Pediatr Psychol.* 1992;17:95-109.
37. Miner J, Krauss B. Procedural sedation and analgesia research: state of the art. *Acad Emerg Med.* 2007;14:170-178.
38. Roback MG, Wathen JE, MacKenzie T, et al. A randomized, controlled trial of IV versus IM ketamine for sedation of pediatric patients receiving emergency department orthopedic procedures. *Ann Emerg Med.* 2006;48:605-612.
39. Heistein LC, Ramaciotti C, Scott WA, et al. Chloral hydrate sedation for pediatric echocardiography: physiologic responses, adverse events, and risk factors. *Pediatrics.* 2006;117:e434-441.

40. Dalal PG, Murray D, Cox T, et al. Sedation and anesthesia protocols used for magnetic resonance imaging studies in infants: provider and pharmacologic considerations. *Anesth Analg*. 2006;103:863-868.
41. Sanborn PA, Michna E, Zurakowski D, et al. Adverse cardiovascular and respiratory events during sedation of pediatric patients for imaging examinations. *Radiology*. 2005;237:288-294.
42. Antmen B, Saşmaz I, Birbiçer H, et al. Safe and effective sedation and analgesia for bone marrow aspiration procedures in children with alfentanil, remifentanil and combinations with midazolam. *Paediatr Anaesth*. 2005;15:214-219.
43. Berkenbosch JW, Graff GR, Stark JM, et al. Use of a remifentanil-propofol mixture for pediatric flexible fiberoptic bronchoscopy sedation. *Paediatr Anaesth*. 2004;14:941-946.
44. Kienstra AJ, Ward MA, Sasan F, et al. Etomidate versus pentobarbital for sedation of children for head and neck CT imaging. *Pediatr Emerg Care*. 2004;20:499-506.
45. Mensour M, Pineau R, Sahai V, et al. Emergency department procedural sedation and analgesia: a Canadian Community Effectiveness and Safety Study (ACCESS). *CJEM*. 2006;8:94-99.
46. Willman EV, Andolfatto G. A prospective evaluation of "ketofol" (ketamine/propofol combination) for procedural sedation and analgesia in the emergency department. *Ann Emerg Med*. 2007;49:23-30.
47. Anderson JL, Junkins E, Pribble C, et al. Capnography and depth of sedation during propofol sedation in children. *Ann Emerg Med*. 2007;49:9-13.
48. Dial S, Silver P, Bock K, et al. Pediatric sedation for procedures titrated to a desired degree of immobility results in unpredictable depth of sedation. *Pediatr Emerg Care*. 2001;17:414-420.
49. Bassett KE, Anderson JL, Pribble CG, et al. Propofol for procedural sedation in children in the emergency department. *Ann Emerg Med*. 2003;42:773-782.
50. Hoffman GM, Nowakowski R, Troshynski TJ, et al. Risk reduction in pediatric procedural sedation by application of an American Academy of Pediatrics/American Society of Anesthesiologists process model. *Pediatrics*. 2002;109:236-243.
51. Schreiner MS, O'Hara I, Markakis DA, et al. Do children who experience laryngospasm have an increased risk of upper respiratory tract infection? *Anesthesiology*. 1996;85:475-480.
52. Fink BR. The etiology and treatment of laryngeal spasm. *Anesthesiology*. 1956;17:569-577.
53. Hampson-Evans D, Morgan P, Farrar M. Pediatric laryngospasm. *Pediatr Anesth*. 2008;18:303-307.
54. Green SM, Kuppermann N, Rothrock SG, et al. Predictors of adverse events with intramuscular ketamine sedation in children. *Ann Emerg Med*. 2000;35:35-42.
55. Wathen JE, Roback MG, Mackenzie T, et al. Does midazolam alter the clinical effects of intravenous ketamine sedation in children? a double-blind, randomized, controlled, emergency department trial. *Ann Emerg Med*. 2000;36:579-588.
56. Warner MA, Warner ME, Warner DO, et al. Perioperative pulmonary aspiration in infants and children. *Anesthesiology*. 1999;90:66-71.
57. Gundappa N, Chikyarappa A. A review of patients with pulmonary aspiration of gastric contents during anesthesia reported to the departmental quality assurance committee. *J Clin Anesth*. 2006;18:102-107.
58. Marik PE. Aspiration pneumonitis and aspiration pneumonia. *N Engl J Med*. 2001;344:665-671.
59. Borland LM, Sereika SM, Woelfel SK, et al. Pulmonary aspiration in pediatric patients during general anesthesia: incidence and outcome. *J Clin Anesth*. 1998;10:95-102.
60. Zaritsky AL, Schexnayder SM, Berg RA, et al. Bradyarrhythmias and tachyarrhythmias. In: Ralston M, Hazinski MF, Zaritsky AL, et al, eds. *PALS Course Guide*. Dallas, TX: American Heart Association; 2006:45.
61. Zaritsky AL, Schexnayder SM, Berg RA, et al. Circulation. In: Ralston M, Hazinski MF, Zaritsky AL, et al., eds. *PALS Course Guide*. Dallas, TX: American Heart Association; 2006:17.
62. Doenicke AW, Roizen M, Kugler J, et al. Reducing myoclonus after etomidate. *Anesthesiology*. 1999;90:113-119.
63. Convulsion. In: Anderson DM, Patwell JM, Plaut K, et al, eds. *Dorland's Illustrated Medical Dictionary*. 31st ed. Philadelphia, PA: WB Saunders Co.; 2007.
64. Robin C, Trieger N. Paradoxical reactions to benzodiazepines in intravenous sedation: a report of 2 cases and review of the literature. *Anesth Prog*. 2002;49:128-132.
65. Kennedy RM, Porter FL, Miller JP, et al. Comparison of fentanyl/midazolam with ketamine/midazolam for pediatric orthopedic emergencies. *Pediatrics*. 1998;102:956-963.
66. Kaplan HI, Sadock BJ, Grebb JA. *Kaplan and Sadock's Synopsis of Psychiatry. Behavioral Sciences Clinical Psychiatry*. 7th ed. Baltimore, MD: Wilkins & Wilkins; 1994.
67. Death. In: Anderson DM, Patwell JM, Plaut K, et al, eds. *Dorland's Illustrated Medical Dictionary*. 31st ed. Philadelphia, PA: WB Saunders Co.; 2007.

### Call for ACEP Research Forum Moderators

Deadline May 29, 2009

The Research Committee/Research Forum sub-committee is looking to increase and update its moderator pool. If you have expertise in areas of emergency medicine research and have the people skills to facilitate, critique and enhance scientific presentations, the ACEP Research Forum wants you. For more information and how to apply, go to [www.acep.org/researchforum](http://www.acep.org/researchforum).

**Appendix E1.** Recommended documentation for sedation research.

**A. SEDATION DOCUMENTATION**

**1. Pre-Sedation Behavioral State**

**Definition:** The patient's behavioral state immediately prior to sedation.

1. Indicate the state that best describes the child's behavior immediately prior to the administration of the sedation drugs:
  - Calm (eg, not crying)
  - Agitated but responds to comforting (eg, briefly stops crying)
  - Agitated and does not respond to comforting (eg, continuous crying)

**2. Efficacy of Sedation**

**Definition:** A successful sedation creates conditions necessary to safely facilitate completion of a procedure through attenuation of pain, anxiety and movement with amnesia or decreased awareness. Patient must fulfill all criteria for a sedation to be considered successful.

1. Sedation was efficacious  YES  NO  
If YES, indicate which of the following criteria were met during the sedation
  - The patient does not have unpleasant recall of the procedure
  - The patient did not experience a sedation-related adverse event, resulting in the abandonment of the procedure
  - The patient did not experience a permanent complication
  - The patient did not have an unplanned admission to hospital or prolonged ED observation
  - The patient did not actively resist or require physical restraint for completion of the procedure

**B. ADVERSE OUTCOME DOCUMENTATION**

**1. Oxygenation**

**1.1 Oxygen Desaturation**  YES  NO

**Definition:** Oxygen desaturation AND one or more intervention(s) are performed with the intention of improving the saturation

1. Baseline oxygen saturation on room air prior to PSA \_\_\_\_\_%
2. Oxygen delivered at start of Sedation phase  NO  YES  
If YES, Method of oxygen delivery:  nasal canula  blow-by  face mask  face mask + non-rebreather  
Flow rate delivered: \_\_\_\_\_ litres/minute
3. Indicate the interventions performed in response to the oxygen desaturation (*indicate ALL that apply*)
  - Vigorous tactile stimulation
  - Oral or nasal airway placement
  - Airway repositioning
  - Application of positive pressure +/- ventilation with bag mask
  - Suctioning
  - Tracheal Intubation
  - Supplementing/increasing oxygen
  - Other \_\_\_\_\_
4. Lowest reliable oxygen saturation measured during the sedation \_\_\_\_\_%

**2. Ventilation**

**2.1 Apnea: central**  YES  NO

**Definition:** Cessation or pause of ventilatory effort AND one or more intervention(s) are performed with the intention of stimulating or assisting ventilation.

1. Indicate the criteria used for recognition (*indicate ALL that apply*)
  - Visual confirmation of cessation/pause of ventilation
  - Loss of CO<sub>2</sub> waveform
  - Cyanosis
  - Other \_\_\_\_\_
  - Oxygen desaturation
2. Indicate the interventions performed in response to the apnea (*indicate ALL that apply*)
  - Vigorous tactile stimulation
  - Application of bag mask *with* assisted ventilation
  - Administration of reversal agents
  - Tracheal intubation
  - Other \_\_\_\_\_

**2.2 Apnea: Obstructive**

**2.2.1 Partial Upper Airway Obstruction**  YES  NO

**Definition:** Manifested by stridor, snoring OR chest wall and suprasternal retractions AND one or more intervention(s) are performed with the intention of relieving the partial airway obstruction.

1. Indicate the criteria used for recognition (*indicate ALL that apply*)
  - Stridor
  - Oxygen desaturation
  - Snoring
  - Other \_\_\_\_\_
  - Chest wall or suprasternal retractions

2. Indicate the interventions performed in response to the partial obstruction (*indicate ALL that apply*)
 

<input type="checkbox"/> Airway repositioning	<input type="checkbox"/> Application of positive pressure with bag mask but <i>without</i>
<input type="checkbox"/> Suctioning	assisted ventilation
<input type="checkbox"/> Oral or nasal airway placement	<input type="checkbox"/> Other _____

**2.2.2 Apnea: Complete Upper Airway Obstruction**    YES    NO

**Definition (general terms):** Ventilatory effort with NO air exchange manifested by absence of upper airway (e.g. stridor or snoring) and breath sounds on auscultation *and* a loss of CO<sub>2</sub> waveform if capnography is used AND the obstruction is relieved by one or more intervention(s) performed with the intention of relieving the complete airway obstruction.

1. Indicate the criteria used for recognition (*indicate ALL that apply*)
 

<input type="checkbox"/> Ventilatory effort with NO air exchange	<input type="checkbox"/> Other _____
<input type="checkbox"/> Loss of CO <sub>2</sub> waveform (if capnography used)	
<input type="checkbox"/> Oxygen desaturation	
2. Indicate the interventions performed in response to the complete obstruction (*indicate ALL that apply*)
 

<input type="checkbox"/> Airway repositioning	<input type="checkbox"/> Application of positive pressure +/- ventilation with bag mask
<input type="checkbox"/> Suctioning	<input type="checkbox"/> Tracheal intubation
<input type="checkbox"/> Oral or nasal airway placement	<input type="checkbox"/> Administration of neuromuscular blockade agents
<input type="checkbox"/> Administration of additional sedation agents	<input type="checkbox"/> Other _____

**2.3 Apnea: Laryngospasm**    YES    NO

**Definition:** Partial or complete upper airway obstruction, *with* oxygen desaturation due to involuntary and sustained closure of the vocal cords AND is NOT relieved by routine airway repositioning maneuvers, suctioning or insertion of a nasal or oral airway

1. Indicate the criteria used for recognition (*indicate ALL that apply*)
 

<input type="checkbox"/> Ventilatory effort with NO air exchange	<input type="checkbox"/> Partial airway obstruction not relieved with airway maneuvers
<input type="checkbox"/> Loss of CO <sub>2</sub> waveform (if capnography used)	<input type="checkbox"/> Other _____
<input type="checkbox"/> Oxygen desaturation	
2. Indicate the interventions performed in response to the laryngospasm (*indicate ALL that apply*)
 

<input type="checkbox"/> Administration of additional sedation agents
<input type="checkbox"/> Application of positive pressure +/- ventilation with bag mask
<input type="checkbox"/> Tracheal intubation
<input type="checkbox"/> Administration of neuromuscular blockade agents
<input type="checkbox"/> Other _____

**3. Clinically Apparent Pulmonary Aspiration**    YES    NO

**Definition:** Suspicion OR confirmation of oropharyngeal or gastric contents in the trachea during the Sedation or Physiologic Recovery phase AND the appearance of respiratory signs and symptoms that were not present prior to the sedation. The new signs and symptoms must present before the end of the ED Recovery phase.

The patient must develop one or more sign or symptom in any of the following three categories:

- (i) Physical Signs: cough, crackles/rales, decreased breath sounds, tachypnea, wheezing, rhonchi OR respiratory distress
- (ii) Oxygen Requirement: decrease in oxygen saturation from baseline requiring supplemental oxygen
- (iii) Chest X-Ray Findings: focal infiltrate, consolidation or atelectasis

1. Indicate if there was physical evidence of regurgitation    NO    YES  
 If YES, was this confirmed by direct visualization of gastric contents in the trachea by laryngoscopy?    NO    YES
2. Indicate ALL signs and symptoms present (*these MUST NOT have been present prior to the sedation*)
 

<input type="checkbox"/> Cough	<input type="checkbox"/> Tachypnea	<input type="checkbox"/> Respiratory distress
<input type="checkbox"/> Crackles/rales	<input type="checkbox"/> Wheeze	<input type="checkbox"/> Need for supplemental oxygen
<input type="checkbox"/> Decreased breath sounds	<input type="checkbox"/> Rhonchi	<input type="checkbox"/> CXR changes
<input type="checkbox"/> Other _____		
3. Indicate the response to the signs and symptoms of aspiration (*indicate ALL that apply*):
 

<input type="checkbox"/> No active intervention	<input type="checkbox"/> Administration of medications
<input type="checkbox"/> Supplemental oxygen	<input type="checkbox"/> Application of positive pressure +/- ventilation with bag mask
<input type="checkbox"/> Other _____	<input type="checkbox"/> Extended observation or admission to hospital
4. Indicate the medications, if any, that were administered: (*indicate ALL that apply*)
 

<input type="checkbox"/> No medications administered	<input type="checkbox"/> Other _____
<input type="checkbox"/> Albuterol or salbutamol	
<input type="checkbox"/> Antibiotics	
<input type="checkbox"/> Steroids	

#### 4. Retching/Vomiting

**Definition:** The motor reflex response characteristic of retching with or without the expulsion of gastric contents through the mouth or nose that occurs during Sedation, ED Recovery or Post-Discharge phases of sedation

1. Indicate whether the patient retched during sedation  
 YES  NO  
If YES, indicate when the retching occurred (*indicate ALL periods of occurrence*)  
 Sedation – Induction  ED Recovery  
 Sedation – Maintenance  Post-Discharge
2. Indicated whether the patient vomited during sedation  
 YES  NO  
If YES, indicate when the vomiting occurred (*indicate ALL periods of occurrence*)  
 Sedation – Induction  ED Recovery  
 Sedation – Maintenance  Post-Discharge
  - a. If YES, indicate the number of times the patient vomited (Consider as a *single* episode if there is <2min between vomits) \_\_\_\_\_
3. Indicate whether the patient received an anti-emetic  NO  YES  
If YES, indicate the reason for administration  as prophylaxis  in response to vomiting  
Indicate which anti-emetic was administered \_\_\_\_\_

#### 5. Cardiovascular Events

##### 5.1. Bradycardia YES NO

**Definition:** Heart rate less than 2 standard deviations below normal for age as described by the AHA in the PALS provider manual during the Sedation or Physiologic Recovery phase AND one or more intervention(s) are performed with the intention of improving the heart rate and cardiac output.

1. Indicate when the bradycardia occurred:  Sedation – Induction  Sedation – Maintenance  ED Recovery – Physiologic
2. Indicate the interventions performed in response to the bradycardia (*indicate ALL that apply*)  
 Suctioning  Application of bag mask *with* assisted ventilation  
 Vigorous tactile stimulation  Tracheal intubation  
 Airway repositioning  Chest compressions  
 Supplemental oxygen  Administration of medications  
 Other \_\_\_\_\_
3. Indicate if medications were administered:  NO  YES  
If YES, indicate what was administered  Atropine  Epinephrine  Reversal agents  Other \_\_\_\_\_
4. Indicate if the bradycardia was isolated or associated with other events:  
 Isolated  With oxygen desaturation  With hypotension  Other \_\_\_\_\_
5. Indicate the lowest heart rate attained: \_\_\_\_\_ beats/min

##### 5.2. Hypotension YES NO

**Definition:** Systolic blood pressure less than the 5<sup>th</sup> percentile for age as defined by the AHA in PALS during the Sedation or Physiologic Recovery phase AND one or more intervention(s) are performed with the intention of improving the blood pressure.

1. Indicate when the hypotension occurred:  Sedation (Induction)  Sedation (Maintenance)  ED Recovery (Physiologic)
2. Indicate the interventions performed in response to the hypotension (*indicate ALL that apply*)  
 IV fluid administration  Administration of medications  
 Chest compressions  Other \_\_\_\_\_
3. Indicate if medications were administered:  NO  YES  
If YES, indicate what was administered  Epinephrine  Dopamine  Reversal agents  Other \_\_\_\_\_
4. Indicate the cause that best fits with the cause of the hypotension:  
 Drug effect  Unknown  
 Co-morbid condition (blood loss, sepsis)  Other \_\_\_\_\_
5. Indicate the lowest blood pressure attained: \_\_\_\_\_ / \_\_\_\_\_ mmHg

